Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly FCF Margin of 779.81% for Q1 2026, up 11639.0% year-over-year from N/an in Q1 2025, and down 158.59% quarter-over-quarter from 301.56% in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported FCF Margin for 12 consecutive years, with 779.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 11639.0% year-over-year to 779.81%; the TTM figure through Mar 2026 stood at 551.05% (up 27254.0% YoY), while the FY2025 annual figure was 584.98%, up 1881.0% from the prior year.
- FCF Margin slipped to 779.81% in Q1 2026 per NTLA's latest filing, from 301.56% in the prior quarter.
- Across five years, FCF Margin topped out at 4283.46% in Q4 2023 and bottomed at 928.33% in Q3 2024.
- Historically, FCF Margin has averaged 402.77% across 5 years, with a median of 698.33% in 2023.
- Annual changes were most pronounced in 2023 — FCF Margin soared 494148 bps — and 2024, when it slumped 494680 bps.
- Intellia Therapeutics' FCF Margin stood at 658.01% in 2022, then soared by 751 bps to 4283.46% in 2023, then slumped by 115 bps to 663.34% in 2024, then surged by 55 bps to 301.56% in 2025, then slumped by 159 bps to 779.81% in 2026.
- Business Quant data shows NTLA's FCF Margin at 779.81% in Q1 2026, 301.56% in Q4 2025, and 565.24% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -1,108.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,108.79% |
| Mar 31, 2026 | -780.34% |
| Dec 31, 2025 | -301.56% |
| Sep 30, 2025 | -558.18% |
| Jun 30, 2025 | -701.02% |
| Mar 31, 2025 | -900.13% |
| Dec 31, 2024 | -669.38% |
| Sep 30, 2024 | -945.19% |
| Jun 30, 2024 | -850.91% |
| Mar 31, 2024 | -425.67% |
| Dec 31, 2023 | 4,933.44% |
| Sep 30, 2023 | -881.53% |
| Jun 30, 2023 | -696.07% |
| Mar 31, 2023 | -897.67% |
| Dec 31, 2022 | -690.94% |
| Sep 30, 2022 | -623.87% |
| Jun 30, 2022 | -618.52% |
| Mar 31, 2022 | -742.29% |
| Dec 31, 2021 | -447.48% |
| Sep 30, 2021 | -965.57% |